5:06 PM
Feb 07, 2018
 |  BC Extra  |  Company News

Cardio/diabetes sales drag down Sanofi earnings

On the heels of a pair of proposed multibillion dollar acquisitions, Sanofi (Euronext:SAN; NYSE:SNY) reported earnings that missed analyst forecasts as the company grapples with a decline in sales for its diabetes and cardiovascular business unit.

The company reported a 4Q17 non-GAAP EPS of €1.06 and sales of €8.69 billion ($10.8 billion) vs. consensus of €1.15 and $8.71 billion ($10.9 billion), respectively. The pharma also guided 2018 EPS growth of...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >